Group 1 - The company, Jiangxi Jindalai Environmental Protection Co., Ltd., has approved an external investment plan to invest in Yunnan Jici Medical Technology Co., Ltd. [2][3] - The investment will be executed in three phases, with a total investment of RMB 150 million in the first phase, followed by RMB 50 million in the second phase, and the remaining funds after obtaining new drug clinical research approval [3][4] - The company aims to establish a concerted action relationship with Hu Min to jointly control Jici Medical in major decisions [3][4] Group 2 - The changes in the investment plan are expected to enhance the company's risk resistance and align with its long-term strategic development, without adversely affecting daily operations [5] - The investment is sourced from the company's own funds, which will not impose significant short-term cash flow pressure [8] - The company acknowledges the uncertainties and risks associated with drug development, including potential delays in clinical trials and regulatory approvals [9][10]

Core Viewpoint - Hualan Co., Ltd. announced a collaboration between its wholly-owned subsidiary, Hainan Lingqing Smart Pharmaceutical Technology Co., Ltd., and a technical team led by former CTO of Insilico Liu Kaixian and Academician Liu Jun from the American Academy of Sciences to establish a joint venture focused on drug repurposing and pharmacovigilance services using knowledge graphs [1][2]. Group 1 - The joint venture will be controlled by Lingqing Smart and will be included in the company's consolidated financial statements [1]. - The venture aims to provide intelligent solutions for drug research and safety management by integrating heterogeneous data sources [1]. - The specific business scope will be defined according to the business registration information [1]. Group 2 - To enhance the long-term development motivation of the joint venture, the company plans to implement a performance-based partnership incentive arrangement linked to business targets [2]. - This incentive will involve transferring partnership shares through Holding Platform 1 to motivate key personnel and others who significantly contribute to the joint venture's development [2]. - The arrangement aims to align the interests of core personnel with the long-term success of the venture, promoting risk-sharing and long-term incentives [2].

2月10日，天眼查融资历程显示，江苏安可瑞齐医疗科技有限公司近日获得"天使轮"融资，涉及融资金 额千万级人民币，投资机构为昆高新集团，薛淀资产，微纳资本。 天眼查信息显示，江苏安可瑞齐医疗科技有限公司的股东为：江苏苏州柒贰玖企业管理合伙企业（有限 合伙）、阎晓平、杨杰、张驰、昆山天使二期投资基金合伙企业（有限合伙）。 来源：市场资讯 资料显示，江苏安可瑞齐医疗科技有限公司法定代表人为浦航，成立于2025年，位于苏州市，是一家以 从事研究和试验发展为主的企业。企业注册资本1183.333333万人民币，并已于2026年完成了天使轮， 交易金额千万级人民币。 通过天眼查大数据分析，江苏安可瑞齐医疗科技有限公司共对外投资了5家企业。 ...

近年来，在相关政策文件、会议精神中，"科技金融""培育壮大耐心资本"屡被提及。那么，金融机构有 哪些积极的实践？科技金融、耐心资本与科创企业、实体经济有哪些共生密码？金融机构、创投企业如 何诠释"耐心"的内涵？ 《金融时报》记者注意到，2026年的科技金融领域正加速发生着一场关于"耐心"的变革。当"急扩产"撞 上"缺资金"，"高技术研发周期"遇上"资本短期回报诉求"，传统金融模式与硬科技企业的成长节奏错配 这一难题正被耐心资本的"活水"慢慢弥合。 与创新同行的耐心 在快节奏的市场环境中，对于渴求快回报的资本而言，"耐心"本身就与时间密切相关，意味着需要长期 的坚守与等待。而"耐心"与资本二者深度融合在一起的具象化模样会是什么？ 一个关于国产医疗级动态血糖仪领跑市场的故事，或许能让我们直观感受到这份与时间为伴、与创新同 行的耐心。 2025年末的一次山东调研行中，《金融时报》记者见到了如今已在市场上广泛使用的国产医疗级动态血 糖仪。与传统的指尖采血、试纸测量不同，一枚拇指大小的可穿戴设备通过一根细长软针扎入上臂外 侧，在传感器有效期内，可每隔5分钟将血糖数据上传到手机App中。2021年底，这一我国首款获得国 ...

《科创板日报》2月10日讯 今日科创板早报主要内容有：高德打车被约谈；三星显示正考虑扩大OLED 面板产能；埃夫特：拟购买盛普股份100%股份。 交通运输新业态协同监管部际联席会议办公室约谈高德打车 交通运输新业态协同监管部际联席会议办公室组织对高德打车进行了约谈。约谈指出了高德打车对合作 网约车平台管理不到位、压低运价、应急处置不当等突出问题，并要求高德打车立即落实约谈要求，深 刻反思，采取针对性措施，确保全面整改到位，切实维护司机群体合法权益。 认购需求空前旺盛 Alphabet料通过发行美元债筹资200亿 《科创板日报》主播小K为您播报。 市场动态 习近平：建设社会主义现代化强国 关键在科技自立自强 9日上午，习近平总书记在位于北京亦庄的国家信创园考察科技创新工作，走进展厅察看人工智能、机 器人等科技创新成果展示，并同科研人员和科技企业负责人代表亲切交流。习近平说，建设社会主义现 代化强国，关键在科技自立自强。要充分发挥我们国家集中力量办大事的优势，把各种优质要素集合起 来攻关，加快解决突出短板问题，实现我们的战略目标。 七部门对头部平台企业和快递企业开展用工行政指导 人力资源社会保障部近日会同中央社会 ...

Virta Health首席执行官萨米·因基宁表示，自己唯一感觉"成功了"的时刻是2008年还清10万美元债务时。他直到37 岁才拥有第一辆车，并且"享受简朴生活"。图片来源：Courtesy of Virta Health 人们一想到市值数十亿美元公司的首席执行官，很容易产生刻板印象：一位西装革履、精致得体的商业 精英，乘坐私人飞机在全球各地参加会议，身边总跟着助理团队。但并非所有企业家都会用浮华的生活 方式来享受成功的成果，有些人只是为终于还清学生贷款而心怀感激。 连续创业者萨米·因基宁在其20年的职业生涯中，一手创立了三家公司，并将其发展壮大，其中包括两 家独角兽公司。作为Virta Health的首席执行官，虽然他凭借商业成功积累了财富，但他并不在意自己的 净资产。事实上，因基宁直到还清银行账户里那笔10万美元的学生贷款，才第一次觉得自己算是"有钱 人"。 因基宁在接受《财富》杂志采访时表示："我人生中只有在那一刻觉得自己很富有。之后，我就再也没 有把心思放在钱上。"2008年，在与人联合创办房地产搜索公司Trulia三年后，他出售了一部分二级市场 股份，税前收入50万美元。"那时我终于有足够的钱还清 ...

Core Viewpoint - The company, Yidu Tech (02158), is actively repurchasing shares, signaling confidence in its value and positively impacting market sentiment [1] Group 1: Share Buyback Activity - On February 9, Yidu Tech announced a share buyback, repurchasing 910,000 shares at approximately HKD 5.77 per share, totaling over HKD 5 million [1] - This marks the company's eleventh consecutive trading day of intensive buybacks, with a cumulative repurchase amount of approximately HKD 58 million [1] - The stock price of Yidu Tech rose by 3.39% on the same day, closing at HKD 5.79, reflecting a positive market response to the buyback [1] Group 2: Analyst Ratings and Market Position - Citigroup maintained a "Buy" rating for Yidu Tech and raised its target price to HKD 11 [1] - The company has established a strong presence in national-level AI medical application pilot projects in regions like Beijing and Henan, enhancing operational efficiency in medical institutions [1] - Yidu Tech's products, such as the Doctor Copilot, and its consumer-facing offering "Yidu Qianyu" demonstrate solid technical capabilities, performing well in accuracy and traceability of medical evidence in tests conducted by Citigroup [1] - The company is positioned in the first tier alongside leading products like Ant Group's "Alfu" and iFlytek's "Xiao Yi," creating a synergistic layout between its To-G (government and hospital) and To-C (consumer) business segments [1]

Core Viewpoint - The company, Yidu Tech (02158), has been actively repurchasing its shares, signaling confidence in its value and positively impacting market sentiment [1] Group 1: Share Buyback Activity - On February 9, Yidu Tech announced a share buyback of 910,000 shares at approximately HKD 5.77 per share, totaling over HKD 5 million [1] - This marks the 11th consecutive trading day of intensive buybacks, with a cumulative repurchase amount of approximately HKD 58 million [1] - The stock price of Yidu Tech rose by 3.39% on the same day, closing at HKD 5.79, reflecting a positive market response to the buyback [1] Group 2: Analyst Ratings and Market Position - Citigroup maintained a "Buy" rating for Yidu Tech and raised its target price to HKD 11 [1] - The company has established a strong presence in national-level AI medical application pilot projects in regions like Beijing and Henan, enhancing operational efficiency in medical institutions [1] - Yidu Tech's products, such as the Doctor Copilot, and its consumer-facing "Yidu Qianyu" demonstrate solid technical capabilities, ranking alongside leading products in accuracy and traceability of medical evidence [1]

Group 1 - The company, Yidu Tech (02158), announced a share buyback plan on February 9, 2026, involving an expenditure of HKD 5.2455 million to repurchase 908,800 shares [1]

"放疗和手术不一样，它不是一刀切开，而是通过外部射线穿透体表，直达病灶，这就意味着射线会经 过很多正常组织。"缑水平进一步解释，"我们团队做的，就是通过人工智能技术精准识别出肿瘤的核心 区域与边界，从而明确手术的入路方式，并提前标注出手术中的危险点，比如血管、神经及周围的风险 器官。" "以前，医生看胃癌CT影像，200多层图像得一张一张'扒拉'着数淋巴结，眼睛熬红了还容易弄混。而借 助AI技术，只用几秒钟就能精准勾画出病灶。"指着电脑屏幕上的肿瘤影像，西安电子科技大学人工智 能学院教授缑水平告诉中青报·中青网记者，这是人工智能（AI）技术帮助临床解决的真问题。 "在我国，医学影像数据量巨大，但有经验的资深医生却数量不足。人工智能就像'超级助手'，可以提 升诊疗效率，有效促进筛查与早期诊断。"缑水平的话，道出了她20多年深耕肿瘤智能诊疗的初心。 为啃下这块"硬骨头"，缑水平带领团队成员一头扎进北京肿瘤医院的临床一线。白天，跟随医生查床、 看影像，记录影像特征；趁着医生休息，他们又在深挖"如何快速区分病灶与正常组织""怎样平衡肿瘤 切除与器官功能保留"等临床的"痛点"问题；到了晚上，再根据医生的不同手术切除方法 ...